Hikal Limited (NSE:HIKAL)
India
· Delayed Price · Currency is INR | Market Cap | 49.33B |
| Revenue (ttm) | 18.22B |
| Net Income (ttm) | 746.02M |
| Shares Out | n/a |
| EPS (ttm) | 6.04 |
| PE Ratio | 66.13 |
| Forward PE | n/a |
| Dividend | 1.20 (0.30%) |
| Ex-Dividend Date | Feb 7, 2025 |
| Volume | 102,953 |
| Average Volume | 274,457 |
| Open | 398.80 |
| Previous Close | 399.45 |
| Day's Range | 384.00 - 404.45 |
| 52-Week Range | 267.25 - 464.75 |
| Beta | 1.32 |
| RSI | 56.94 |
| Earnings Date | May 9, 2025 |
About Hikal
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs). Its Crop Protection segment manufactures pesticides and herbicides, wh... [Read more]
Financial Performance
In 2023, Hikal's revenue was 17.85 billion, a decrease of -11.79% compared to the previous year's 20.23 billion. Earnings were 696.02 million, a decrease of -11.20%.
Financial StatementsNews
Hikal shares drop over 6% after US FDA issues six observations for Jigani facility
Hikal Ltd’s stock tumbled over 6% in early trade after the company announced it received six observations from the US Food and Drug Administration (US FDA) for its Jigani facility in Bengaluru, Karnat...
Hikal receives 6 observations for Jigani facility from US FDA
Hikal Ltd has successfully completed a US Food and Drug Administration (US FDA) inspection at its Jigani facility in Bengaluru, Karnataka. The inspection, conducted from February 3 to February 7, 2025...